Medical Analysis

Comprehensive Medical Analysis of Factor VIII, Hemophilia A, Coagulation Pathways, and Clinical Biomarkers

Introduction to Factor VIII and Coagulation Disorders

Factor VIII, commonly known as the antihemophilic factor, is the essential protein that is deficient or defective in patients with classical hemophilia and Von Willebrand syndrome [3, 4]. Beyond its classical role in bleeding disorders, elevated Factor VIII has been identified as an independent venous thromboembolism (VTE) risk factor in cancer, although the precise biological basis of this increase remains unknown [6]. In venous thromboembolism (VTE), a blood clot forms inside a vein, encompassing conditions such as deep vein thrombosis (DVT) and pulmonary embolism (PE) [6]. Additionally, Factor VIII is utilized in the form of an antigen in immunohistochemistry (IHC) studies [4].

Physiological Role of Factor VIII and Intrinsic Coagulation Pathway Mechanisms

Whenever there is an injury of any type, certain proteins, including Factor VIII, come together to form blood clots and quickly stop bleeding [1, 2]. Factor VIII related antigen is used as a target for IHC, where endothelial cells, megakaryocytes, platelets, and mast cells normally stain positive [4]. In humans, Factor VIII is encoded by the F8 gene [4]. Defects in this gene result in hemophilia A, an X-linked bleeding disorder [4]. Notably, hemophilia A is seven times more common than hemophilia B [4].

During contact activation triggered by surface injury by any means, Factor XII is converted to Factor XII A, which subsequently activates Factor XI to Factor XI A [1]. Factor XI A then activates Factor IX to Factor IX A [1]. The activation of Factor VIII results from limited proteolysis catalyzed by thrombin or Factor Xa, which binds the Factor VIII substrate over extended interactive surfaces [1, 7]. Activated Factor VIII (Factor VIII A) combines with Factor IX A to activate Factor X into Factor X A [1]. Factor Xa is a vital serine protease that cleaves prothrombin to generate thrombin and lies at the crossroads of the extrinsic and intrinsic coagulation pathways [1, 7]. Only a small amount of Factor Xa is required to generate many molecules of thrombin [1]. In the common pathway, the prothrombinase complex converts prothrombin (Factor II) into thrombin (Factor II A), which subsequently converts fibrinogen (Factor I) into fibrin (Factor I A) and activates Factor XIII to Factor XIII A, culminating in stable clot formation [1, 7].

Clinical Indications for Factor VIII Testing

Diagnostic testing and clinical evaluation of Factor VIII are indicated in several specific scenarios:

• Haemophilia A [4, 5].

• To screen unexplained bleeding disorders [10].

• Carrier Testing [4, 5].

• Preoperative assessment [10].

• Prenatal Diagnosis [4, 5].

• Abnormal Coagulation Profile Results [10].

Patient Instructions Prior to Coagulation Testing

To ensure accurate diagnostic results, patients must adhere to specific pre-test instructions:

• Avoid anticoagulants such as Warfarin for at least 2 weeks prior to testing [10].

• Avoid direct Xa, heparin, and thrombin inhibitors for at least 3 days prior to testing [10].

• Do not draw blood samples from a heparinized catheter [10].

Methods of Detection and Specimen Collection Protocols

Citrated Plasma Collection

Collect 9 parts of blood relative to 1 part of a 3.8% Trisodium citrate solution present in the collection vial [10]. Separate the plasma immediately through centrifugation and freeze it rapidly [10]. Transport the specimen to the laboratory on dry ice in a suitable container [10]. As far as possible, carry out testing within four hours from the time of specimen collection [10].

Immunohistochemistry (IHC)

Formalin-fixed, paraffin-embedded tissue blocks are utilized for this test to evaluate tissue antigen expression [4].

Laboratory Assays: Two-Stage Factor VIII Assays and Chromogenic Substrates

Factor VIII evaluation can be performed using complex functional assays [10]. Two-stage Factor VIII assays combine diluted patient plasma with calcium ions (Ca2+), Factor V, and phospholipids (PL) [1, 10]. Specifically, adsorbed patient plasma is mixed with Factor V, activated serum, phospholipid, and Ca2+ to initiate coagulation and generate Factor Xa [1, 10]. After a fixed period of incubation, an aliquot of this mixture is added to an aliquot of normal plasma, and the time required for clot formation is measured [10]. Alternatively, chromogenic assays utilize normal plasma, Ca2+, phospholipids, and Factor X to generate Factor Xa, reacting with a synthetic peptide substrate coupled to paranitroaniline (PNA) to measure optical density (OD) [10].

Normal Reference Ranges and Age-Related Variations

A normal Factor VIII activity value ranges from 50% to 150% of the laboratory control or reference value [10]. Normal value ranges may vary slightly among different laboratories, as some facilities use different measurements or test different sample cohorts [10]. Individuals with activity levels less than 50% are considered to be suffering from Hemophilia A [4, 5]. However, clinical severity depends directly on how profoundly the activity is reduced [4, 5].

Antigen Staining Patterns and Internal Controls in IHC

In immunohistochemical evaluations, Factor VIII takes a cytoplasmic stain [4]. Normal vascular endothelium acts as a reliable positive internal control during tissue analysis [4].

Causes of Abnormally Low Factor VIII Activity

Abnormally low activity levels of Factor VIII can be observed in a variety of congenital and acquired clinical conditions:

• Hemophilia A [4, 5]

• Acquired Factor VIII inhibitors [8, 9]

• von Willebrand Disease [3]

• Liver disease [12]

• Disseminated intravascular coagulation (DIC) [7]

• Vitamin K deficiency [12]

• Autoimmune disorders with Factor VIII antibodies [8, 9]

• Combined Factor V and VIII deficiency [12]

• Severe malnutrition [12]

• Critical illness [11, 12]

Activity Levels and Clinical Severity of Factor VIII Deficiency

Prognostic Significance of Factor VIII

Elevated Factor VIII levels have been shown to be an independent risk factor for deep venous thrombosis and pulmonary embolism [6, 11]. Furthermore, Factor VIII-related antigen is a well-established and recognized marker of endothelial cells, proving particularly useful in identifying vascular invasion in follicular carcinoma of the thyroid [4].

Factor VIII Immunohistochemistry (IHC) Results Interpretation

Diagnostic Utility Across Clinical Scenarios

Comprehensive Summary of Clinical Significance

For Non-Medicos

Understanding Factor VIII and Blood Clotting

Factor VIII is a vital protein in your body that teams up with other clotting factors whenever a blood vessel is injured to stop bleeding quickly [1, 2]. When this protein is missing or doesn’t work properly, it leads to a bleeding disorder known as Hemophilia A [4]. Doctors also look at Factor VIII to evaluate risks for abnormal blood clots in veins or to study tissue samples under a microscope [4, 6].

Preparing for Your Blood Test

Before taking a Factor VIII test, you must avoid certain medications like blood thinners (Warfarin, heparin, or direct Xa inhibitors) because they can interfere with accurate results [10]. It is also essential that blood is drawn directly from a vein rather than through a heparinized catheter to prevent sample contamination [10].

What Your Test Results Mean

Normal Factor VIII activity ranges from 50% to 150% [10]. Levels dropping below 50% suggest Hemophilia A, with the severity classified as mild, moderate, or severe depending on how low the percentage falls [4, 5]. Monitoring these levels helps physicians manage bleeding risks, adjust replacement therapies, and ensure safe surgical outcomes [5, 10].

References:

1. Mann, K. G. (1999). Biochemistry and physiology of blood coagulation. Thrombosis and Haemostasis, 82(2), 165–174.

2. Furie, B., & Furie, B. C. (2005). Thrombus formation in vivo. Journal of Clinical Investigation, 115(12), 3355–3362.

3. Sadler, J. E. (1998). Biochemistry and genetics of von Willebrand factor. Annual Review of Biochemistry, 67, 395–424.

4. Graw, J., et al. (2005). Factor VIII: structure and relation to disease. Nature Reviews Genetics, 6(6), 461–474.

5. White, G. C., et al. (2001). Definitions in hemophilia: recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thrombosis and Haemostasis, 85(3), 560.

6. Koster, T., et al. (1995). Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. The Lancet, 345(8943), 152–155.

7. Esmon, C. T. (2000). Regulation of blood coagulation. Biochimica et Biophysica Acta (BBA) – Protein Structure and Molecular Enzymology, 1477(1-2), 349–360.

8. Astermark, J. (2006). FVIII inhibitors: pathogenesis and management. Seminars in Hematology, 43(3 Suppl 2), S3–S7.

9. Ortel, T. L. (2001). Acquired hemophilia: a current review of management. Autoimmunity Reviews, 1(4), 213–219.

10. Triplett, D. A. (2000). Coagulation assays. American Journal of Clinical Pathology, 114(Suppl 1), S98–S111.

11. Jenny, N. S., et al. (2002). Biomarkers of ischemic heart disease: predictive value of factor VIII and von Willebrand factor. Circulation, 106(12), 1445–1450.

12. Peyvandi, F., et al. (2002). Rare hereditary deficiencyes of coagulation factors. Thrombosis and Haemostasis, 88(6), 916–928.

FAQ’s:

• What is Factor VIII?
  An essential blood protein deficient or defective in classical hemophilia and Von Willebrand syndrome.
• How does Factor VIII help clotting?
  It combines with other proteins during an injury to form blood clots and stop bleeding.
• What gene encodes Factor VIII?
  It is encoded by the F8 gene, and defects lead to X-linked hemophilia A.
• What are the testing indications?
  Indications include hemophilia A, unexplained bleeding, carrier testing, and preoperative assessments.
• What medications must be avoided?
  Avoid Warfarin for two weeks and direct Xa, heparin, or thrombin inhibitors for three days.
• How is citrated plasma collected?
  Collect nine parts blood to one part 3.8% Trisodium citrate, separate plasma, and freeze rapidly.
• What is normal activity range?
  A normal value ranges from 50% to 150% of the laboratory reference control.
• What causes low activity levels?
  Causes include hemophilia A, acquired inhibitors, von Willebrand disease, and liver or critical illness.
• What activity indicates severe deficiency?
  Activity levels below 1% indicate severe Factor VIII deficiency and high bleeding risks.
• Why is elevated Factor VIII risky?
  High levels serve as an independent risk factor for deep venous thrombosis and pulmonary embolism.

Related  Tests

• Activated Partial Thromboplastin Time (aPTT) Test